Publications by authors named "D E Oishi"

Sepsis is characterized by a concomitant early pro-inflammatory response by immune cells to an infection, and an opposing anti-inflammatory response that results in protracted immunosuppression. The primary pathological event in sepsis is widespread programmed cell death, or cellular self-sacrifice, of innate and adaptive immune cells, leading to profound immunological suppression. This severe immune dysfunction hampers effective primary pathogen clearance, thereby increasing the risk of secondary opportunistic infections, latent viral reactivation, multiple organ dysfunction, and elevated mortality.

View Article and Find Full Text PDF

Introduction: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is used as an intra-aortic balloon occlusion in Japan; however, protocols for its effective use in different conditions have not been established. This study aimed to summarize the strategies of REBOA use in severe torso trauma.

Methods: Twenty-nine cases of REBOA for torso trauma treated at our hospital over 5 years were divided into hemodynamically unstable (HU) ( = 12), cardiac arrest (CA) ( = 13), and hemodynamically stable (HS) ( = 4) groups.

View Article and Find Full Text PDF

M2-like tumor-associated macrophages (M2-TAMs) in cancer tissues are intimately involved in cancer immunosuppression in addition to growth, invasion, angiogenesis, and metastasis. Hence, considerable attention has been focused on cancer immunotherapies targeting M2-TAMs. However, systemic therapies inhibit TAMs as well as other macrophages important for normal immune responses throughout the body.

View Article and Find Full Text PDF
Article Synopsis
  • Microsatellite instability (MSI) and POLD1 mutations are more common in colorectal tumours related to polyposis syndrome, but rarely occur in breast tumours.
  • A case of a young patient with a metastatic luminal B breast tumour and a strong family history of cancer revealed a Variant of Uncertain Significance (VUS) in POLD1, leading to further investigation of MSI which tested positive.
  • Current research suggests that pembrolizumab, an immunotherapy drug, may be a more effective treatment for tumours showing MSI compared to traditional chemotherapy.
View Article and Find Full Text PDF